Phase 2 topline
Topline data from the Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis
TLSA · Tiziana Life Sciences Ltd · Foralumab (intranasal) · Non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
Sources and detail
- Float
- No public float has been reported at a usable date.
- Stake
- Research for this company needs an account. The sample companies are fully interactive without one.
- Runway vs event
- Cash or burn is missing, so no runway verdict is made.
- Financing
- No financing filing in the period covered.
- Specialist holders
- No specialist 13F quarter has been read for this issuer.
- Insider net 90d
- No open-market insider transaction was filed in the window.
What happened
Ahead of its window
The stated window has not opened yet.
Sources (1)
- SEC · ea030608701ex99-1.htm
sec filing · published 2026-09-21 · retrieved 2026-09-22
“Tiziana expects to lock the database this week, and announce 12-week treatment topline data in October.”
Research
This event is not joined to a researched indication.
Research date unknown
Market
Market linking is switched off.
Quotes elsewhere
This desk holds no price. These go to the venues that publish one.
What counts as each outcome
Resolved by the sponsor's topline disclosure of the trial's primary endpoint: met as pre-specified is success; missed is failure; endpoints split across doses or cohorts is mixed.
Missing inputs
- issuer_facts: not collected
- public_float_usd: not collected
- shares_outstanding: not collected
- cash_and_investments: not collected
- operating_cash_flow: not collected
- quarterly_burn: not collected
- runway_quarters: not collected
Event row last changed 2026-09-22 · filing signals evaluated 2026-09-22
What changed on this event
- — · created · event · — → Topline data from the Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis · extraction-seam
- — · status · review_state · pending → published · verified against Tiziana's 2026-09-21 press release (EX-99.1): 'Tiziana expects to lock the database this week, and announce 12-week treatment topline data in October.'
This is a dated event and its evidence, not a forecast of its outcome. No price, implied move or market probability is collected or shown anywhere on this page.
